Literature DB >> 17592537

Understanding the natural biology of kidney cancer: implications for targeted cancer therapy.

Tobias Klatte1, Allan J Pantuck, Mark D Kleid, Arie S Belldegrun.   

Abstract

During the past several decades, there has been a significant increase in the understanding of the biology, clinical behavior, and prognostic factors of renal cell carcinoma (RCC). Such progress has led to greater sophistication in the diagnosis and classification of RCC. Here, we review recent advances in our knowledge of the biologic characteristics of RCC that have resulted in notable achievements in staging, prognosis, patient selection, and treatment.

Entities:  

Year:  2007        PMID： 17592537      PMCID： PMC1892626     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  77 in total

1.  Inherited susceptibility to uterine leiomyomas and renal cell cancer.

Authors:  V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

Review 3.  Cytogenetic classification of renal cell cancer.

Authors:  E van den Berg; T Dijkhuizen; J W Oosterhuis; A Geurts van Kessel; B de Jong; S Störkel
Journal:  Cancer Genet Cytogenet       Date:  1997-05

4.  Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells.

Authors:  S Pathak; L C Strong; R E Ferrell; A Trindade
Journal:  Science       Date:  1982-09-03       Impact factor: 47.728

5.  Hereditary renal-cell carcinoma associated with a chromosomal translocation.

Authors:  A J Cohen; F P Li; S Berg; D J Marchetto; S Tsai; S C Jacobs; R S Brown
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

Review 6.  Targeted agents for the treatment of advanced renal cell carcinoma.

Authors:  Walter M Stadler
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

7.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 8.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

Authors:  John S Lam; Oleg Shvarts; John T Leppert; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

9.  Prognostic significance of the mode of detection in renal tumours.

Authors:  J-J Patard; A Rodriguez; N Rioux-Leclercq; F Guillé; B Lobel
Journal:  BJU Int       Date:  2002-09       Impact factor: 5.588

10.  Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas.

Authors:  G Kovacs; P Brusa; W De Riese
Journal:  Int J Cancer       Date:  1989-03-15       Impact factor: 7.396
View more
  16 in total

1.  Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53.

Authors:  Z-G Shi; S-Q Li; Z-J Li; X-J Zhu; P Xu; G Liu
Journal:  Clin Transl Oncol       Date:  2014-07-16       Impact factor: 3.405

Review 2.  Tumor biology and prognostic factors in renal cell carcinoma.

Authors:  David S Finley; Allan J Pantuck; Arie S Belldegrun
Journal:  Oncologist       Date:  2011

3.  Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma.

Authors:  Ateesha F Mohamed; A Brett Hauber; Maureen P Neary
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

4.  Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma.

Authors:  Hyun-Jung Lee; Zhe Long Liang; Song Mei Huang; Jae-Sung Lim; DO-Young Yoon; Hyo-Jin Lee; Jin Man Kim
Journal:  Oncol Lett       Date:  2011-12-02       Impact factor: 2.967

5.  Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Authors:  Chaitanya R Divgi; Robert G Uzzo; Constantine Gatsonis; Roman Bartz; Silke Treutner; Jian Qin Yu; David Chen; Jorge A Carrasquillo; Steven Larson; Paul Bevan; Paul Russo
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

6.  Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.

Authors:  Mehmet Asim Bilen; Amado J Zurita; Nasreen A Ilias-Khan; Hsiang-Chun Chen; Xuemei Wang; Alper Y Kearney; Sherie Hodges; Eric Jonasch; Shixia Huang; Aarif Yusuf Khakoo; Nizar M Tannir
Journal:  Oncologist       Date:  2015-08-25

7.  The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.

Authors:  Bin Huang; Kaiyuan Cao; Xiubo Li; Shengjie Guo; Xiaopeng Mao; Zhu Wang; Jintao Zhuang; Jincheng Pan; Chengqiang Mo; Junxing Chen; Shaopeng Qiu
Journal:  J Exp Clin Cancer Res       Date:  2011-09-28

8.  MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer.

Authors:  Joanna Boguslawska; Anna Wojcicka; Agnieszka Piekielko-Witkowska; Adam Master; Alicja Nauman
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

9.  Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.

Authors:  Susanne Fuessel; Kati Erdmann; Helge Taubert; Andrea Lohse-Fischer; Stefan Zastrow; Matthias Meinhardt; Karen Bluemke; Lorenz Hofbauer; Paolo Fornara; Bernd Wullich; Gustavo Baretton; Viktor Magdolen; Manfred P Wirth; Matthias Kotzsch
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

10.  Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130.

Authors:  Piotr Poplawski; Alicja Nauman
Journal:  Thyroid Res       Date:  2008-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.